AI assistant
BOSTON SCIENTIFIC CORP — Director's Dealing 2025
Jan 3, 2025
29821_dirs_2025-01-03_413a6b86-67b7-4788-a188-bda2f9b290b9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2025-01-01
Reporting Person: Sorenson John Bradley (EVP, Global Operations)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-01-01 | Common Stock | M | 4469.0000 | $0.0000 | Acquired | 41565.0000 | Direct |
| 2025-01-01 | Common Stock | F | 2127.0000 | $89.3200 | Disposed | 39438.0000 | Direct |
| 2025-01-02 | Common Stock | S | 4119.0000 | $90.0200 | Disposed | 35319.0000 | Direct |
| 2025-01-03 | Common Stock | S | 2342.0000 | $89.8587 | Disposed | 32977.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-01-01 | Performance Share Units | $ | M | 4469.0000 | Disposed | 2024-12-31 | Common Stock (4469.0000) | Direct |
Footnotes
F1: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.
F2: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
F3: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.524 to $90.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.